Literature DB >> 19459198

Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab.

Kevin Windebank1, Tom Walwyn, Richard Kirk, Gareth Parry, Asif Hasan, Nick Bown, Bridget Wilkins.   

Abstract

BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL). PROCEDURE: We reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit.
RESULTS: There were 15 episodes in 13 patients including four cases of EBV-driven Burkitt-type disease with t(8;14) translocations presenting with advanced stage disease. The first case was treated with a variety of low dose chemotherapy combinations. Despite problems during therapy he obtained complete remission, but died from complications of pre-existing cardiac allograft vasculopathy 7 months later. The subsequent three cases were treated with a UKCCSG low stage lymphoma protocol, NHL 9001 and Rituximab. They remain in complete remission.
CONCLUSIONS: In the context of PTLD the prognostic significance of advanced stage EBV-driven BLL with the t(8;14) translocation may be different to that in immunocompetent children. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19459198     DOI: 10.1002/pbc.22070

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.

Authors:  T G Gross; M A Orjuela; S L Perkins; J R Park; J C Lynch; M S Cairo; L M Smith; R J Hayashi
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

Review 2.  Advances in paediatric cancer treatment.

Authors:  Federica Saletta; Michaela S Seng; Loretta M S Lau
Journal:  Transl Pediatr       Date:  2014-04

Review 3.  Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra.

Authors:  Francesca Montanari; Manuela Orjuela-Grimm
Journal:  Curr Hematol Malig Rep       Date:  2021-02-05       Impact factor: 3.952

4.  Posttransplant lymphoproliferative disorders.

Authors:  Hazem A H Ibrahim; Kikkeri N Naresh
Journal:  Adv Hematol       Date:  2012-04-17

Review 5.  Rituximab is Indispensable for Pediatric Heart Transplant Recipients Developing Post Transplant Lymphoproliferative Disorders.

Authors:  R Karbasi-Afshar; S Taheri
Journal:  Iran J Ped Hematol Oncol       Date:  2013-07-22

6.  Remission of late-onset post-heart transplantation lymphoproliferative disorder following treatment with rituximab and modified mini-CHOP chemotherapy: A case report.

Authors:  Qiang Huang; Tianxin Yang; Xing Jin; Xuming Ni; Haiyan Qi; Zhikun Yan
Journal:  Exp Ther Med       Date:  2016-05-05       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.